CLEVELAND, Nov. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB), announced today that the Company's Chief Scientific Officer, Andrei Gudkov, Ph.D, D. Sci., will both co-chair a panel and present data from a recent study conducted by Cleveland BioLabs at the Radiation Research Society Annual Meeting, November 4-8, in Philadelphia, PA.

Dr. Gudkov will co-chair the panel entitled, "Radio-Protectants, Radio- Therapeutics, Radiation Damage Mechanisms" on Monday, November 6. The panel is organized and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), which coordinates and funds radioprotection research in academic and private entities in the US. The panel will discuss progress in discovery and development of radioprotectants in research organizations sponsored by NIAID, including Cleveland BioLabs.

Dr. Gudkov's presentation, entitled "Radioprotection by Targeting Toll- like Receptors by Microbial Products," will describe the Company's recent animal studies that demonstrate the broad time window of protection and mitigating effect of the Company's lead radioprotectants, CBLB502 and CBLB612, under conditions of lethal irradiation.

Protectan CBLB502 had previously demonstrated its powerful protective effect when injected prior to exposure in a study where it rescued more than 70% of lethally irradiated primates and substantially reduced radiation- associated tissue injuries. CBLB502 is the first compound of its kind to provide protection from both hematopoietic (immune system) and gastrointestinal radiation-induced damage. CBLB502 is undergoing an accelerated development program under the FDA two-animal rule, which requires the Company to show efficacy in two animal species (including primates) and only safety in humans. The Company's second radioprotectant in development, Protectan CBLB612, has shown to provide a significantly broad time window of protection of the hematopoietic (immune system) in mouse studies. Together, CBLB502 and CBLB612 will cover all possible scenarios that may require protection of humans from the threat of radiation.

Dr. Gudkov is Chief Scientific Officer of Cleveland BioLabs, Inc., Chairman of the Department of Molecular Genetics at the Cleveland Clinic's Lerner Research Institute and Professor of Biochemistry at Case Western Reserve University.

The Radiation Research Society is the largest national organization of radiation biologists and physicians that was formed to execute three primary objectives: to encourage in the broadest manner the advancement of radiation research in all areas of the natural sciences; to facilitate cooperative research between the disciplines of physics, chemistry, biology and medicine in the study of the properties and effects of radiation; and to promote dissemination of knowledge in these and related fields through publications, meetings and educational symposia.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."

     The Global Consulting Group
     Rachel Levine
     T: (646) 284-9439